SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 71.07+0.5%Jul 12 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen4/6/2005 4:23:26 AM
   of 347
 
GenoMed Speaks Today at 1st Annual World Congress Leadership Summit on Disease Management and Chronic Care

Contact: Dr. David Moskowitz
GenoMed, Inc. tel. 314-983-9933 dwmoskowitz@genomed.com

April 5, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced that its Chairman and CEO, Dr. David Moskowitz, has been invited to speak today at The 1st Annual World Congress Leadership Summit on Disease Management and Chronic Care.

This conference, held outside Washington, DC (http://www.worldcongress.com/wcls/ccd/index.cfm) presents the nation's best practices and thought leaders in implementing successful disease management programs that produce positive clinical and financial outcomes. The conference agenda was designed to address the market demands from employers and public purchasers as well as the leading edge programs offered by health care insurers and providers. The agenda highlights legislative trends that impact the adoption and scope of disease management programs including updates from the Centers for Medicaid and Medicare (CMS) on its Chronic Care Improvement Program.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "We've been invited to this inaugural conference because our business model consists of using genomics to improve public health, and we've been uniquely successful at it so far for diabetes, hypertension, and emphysema, which together affect over 85 million Americans."

Continued Dr. Moskowitz, "GenoMed's business model is ideal for today's political climate. It is tailor-made for Health Savings Accounts (HSA's) and Consumer-Directed Health Care (CDHC). In addition to educating health plans about its Next Generation DM(tm) services, GenoMed is also encouraging patients who control their own Health Savings Account or who can afford $67 a month out-of-pocket to sign up themselves for GenoMed's services."

About GenoMed

GenoMed has found what it believes to be the major gene for aging, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see treatment successes for autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed has recently found several thousand genes for the top six solid cancers--breast, colon, lung, ovarian, pancreatic, and prostate--and expects to have new diagnostic tools ready for clincal trials soon, with new cancer chemotherapy to follow.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext